IP Library Granted Patent US 11,221,328
Granted Patent B2
US 11,221,328 · App. 16/491,559 · Granted Jan 11, 2022

Hypoxic NK cells and methods therefor

Inventors: Patrick Soon-Shiong (Culver City, CA); Shahrooz Rabizadeh (Culver City, CA); Kayvan Niazi (Culver City, CA); Stephen Charles Benz (Culver City, CA); Laurent H. Boissel (Culver City, CA); Hans Klingemann (Culver City, CA); Barry J. Simon (Culver City, CA)
Assignee: NantCell, Inc.
G01N33/5047C12N5/0646C12Q1/6886G16H50/30C12Q2600/158G01N2800/7014G01N2800/7038
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,221,328
App. No.
16/491,559
Granted
Jan 11, 2022
Kind
B2
Abstract

Detection of under-expression of selected genes in NK cells is used to confirm a hypoxic tumor microenvironment that is ordinarily suppressive with respect to ADCC and cytotoxic cell killing of NK cells. Most notably, while hypoxia is known to upregulate HIF-1α and genes under the control of HIF-1α, hypoxia in a tumor microenvironment led to under-expression of selected genes, including HIF-1α. Thus, gene expression analysis of certain genes on NK cells can be used to detect conditions in a tumor that would indicate use of haNK cells.

Claims (7)

1. A method of treating a tumor in a human patient having a hypoxic tumor microenvironment, the method comprising:

isolating natural killer (NK) cells from a blood sample taken from the patient;

quantifying expression of at least one hypoxia-related gene in the isolated NK cells, wherein the hypoxia related gene is HIF-1α, and wherein the NK cells under-express the at least one hypoxia-related gene relative to an expression level of the at least one hypoxia-related gene in an NK cell at normoxic conditions; and

administering an effective amount of allogenic NK92 cells expressing a high-affinity variant CD16 (haNK) cells to the patient whose isolated NK cells under-express the at least one hypoxia-related gene.

2. The method of claim 1 wherein the NK cells are isolated using magnetic separation and an antibody specific to NK cells.

3. The method of claim 1 wherein quantifying expression is performed using quantitative rtPCR or RNAseq.

4. The method of claim 1 wherein the at least one hypoxia-related gene is under-expressed by a log 2-fold change of at least 2.0.

Assignments (4)
SECURITY INTEREST Recorded Jan 2, 2024
From: IMMUNITYBIO, INC.; NANTCELL, INC.; RECEPTOME, INC.; VBC HOLDINGS LLC; ALTOR BIOSCIENCE, LLC; ETUBICS CORPORATION; IGDRASOL, INC.
To: INFINITY SA LLC, AS PURCHASER AGENT
Reel/Frame 066179/0074 →
NUNC PRO TUNC ASSIGNMENT Recorded Jul 22, 2021
From: SIMON, BARRY J.
To: NANTKWEST, INC.
Reel/Frame 056951/0439 →
NUNC PRO TUNC ASSIGNMENT Recorded Mar 30, 2021
From: BOISSEL, LAURENT H.; KLINGEMANN, HANS
To: NANTKWEST, INC.
Reel/Frame 055768/0965 →
CORRECTIVE ASSIGNMENT TO CORRECT THE FIRST CONVEYING PARTY NAME PREVIOUSLY RECORDED AT REEL: 54938 FRAME: 786. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Jan 25, 2021
From: SOON-SHIONG, PATRICK; RABIZADEH, SHAHROOZ; NIAZI, KAYVAN; NANTOMICS, LLC
To: NANTCELL, INC.
Reel/Frame 055592/0271 →
Continuity (2)
Provisional Application 62468863 · Mar 8, 2017
Related Publication 20200041490A1 · Feb 6, 2020